Maze Therapeutics, Inc. (MAZE)
Every FINRA and SEC series the site collects for Maze Therapeutics, Inc.: short interest with days to cover, daily short sale volume, fails to deliver and Form 4 insider trades. Listed on Nasdaq, classified by the SEC as biological products, (no diagnostic substances).
6.0M
Short interest
settlement 2026-08-14
16.2
Days to cover
+5.5% vs prior
15.8%
Short share of volume
2026-09-11
35
Fails to deliver
settlement 2026-08-14
-$4.5M
Insider flow, 90 days
0 buys, 28 sells
As of 2026-09-11.
Short interest
FINRA, twice a month; the last 12 months shown, all 37 settlements in the JSONAs of 14 August 2026, short interest in MAZE is 5,988,933 shares, up 463,655 shares over the last month. Over the last 37 readings it ranged from 1,195,075 shares (14 February 2025) to 5,988,933 shares (14 August 2026). The latest reading sits at the top of that range. At the reported average volume of 370K shares a day that is 16.2 days to cover, a crowded short.
Embed this chartfree, with the attribution line it carries
<iframe src="https://xoomar.com/embed/stocks/maze" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-08-14 | 5,988,933 | +5.5% | 370,295 | 16.17 |
| 2026-07-31 | 5,678,545 | +2.8% | 357,598 | 15.88 |
| 2026-07-15 | 5,525,278 | -0.0% | 651,947 | 8.48 |
| 2026-06-30 | 5,527,117 | +36.2% | 1,028,368 | 5.37 |
| 2026-06-15 | 4,057,146 | +4.1% | 527,440 | 7.69 |
| 2026-05-29 | 3,897,022 | -1.4% | 442,125 | 8.81 |
| 2026-05-15 | 3,950,970 | -9.2% | 533,249 | 7.41 |
| 2026-04-30 | 4,349,436 | +14.6% | 770,868 | 5.64 |
| 2026-04-15 | 3,795,902 | -2.4% | 1,007,473 | 3.77 |
| 2026-03-31 | 3,890,308 | +8.3% | 1,615,820 | 2.41 |
| 2026-03-13 | 3,591,005 | +4.4% | 566,914 | 6.33 |
| 2026-02-27 | 3,438,552 | +2.5% | 332,322 | 10.35 |
| 2026-02-13 | 3,356,466 | +22.4% | 608,007 | 5.52 |
| 2026-01-30 | 2,741,979 | +6.3% | 465,420 | 5.89 |
| 2026-01-15 | 2,580,026 | -1.0% | 314,401 | 8.21 |
| 2025-12-31 | 2,605,655 | +17.1% | 499,038 | 5.22 |
| 2025-12-15 | 2,224,690 | +0.2% | 426,903 | 5.21 |
| 2025-11-28 | 2,220,820 | -8.9% | 388,477 | 5.72 |
| 2025-11-14 | 2,438,054 | +3.1% | 449,162 | 5.43 |
| 2025-10-31 | 2,363,802 | +2.5% | 272,925 | 8.66 |
| 2025-10-15 | 2,305,717 | -6.4% | 380,404 | 6.06 |
| 2025-09-30 | 2,463,784 | +50.8% | 740,935 | 3.33 |
| 2025-09-15 | 1,634,122 | -5.3% | 931,992 | 1.75 |
| 2025-08-29 | 1,725,065 | -3.0% | 408,304 | 4.22 |
Daily short volume
FINRA Reg SHO, last 60 sessions. JSONAs of 11 September 2026, the short share of MAZE volume is 15.8%, down 71.2 points over the last five sessions. Over the last 52 readings it ranged from 15.8% (11 September 2026) to 91.5% (27 July 2026). The latest reading sits at the bottom of that range. The latest reading is 51.4 points below the 30-session average of 67.2%, on 753K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-09-11 | 119K | 753K | 15.8% | 0 |
| 2026-09-10 | 433K | 782K | 55.4% | 0 |
| 2026-09-09 | 85K | 145K | 58.3% | 10,849 |
| 2026-09-08 | 107K | 161K | 66.0% | 0 |
| 2026-09-04 | 57K | 90K | 64.0% | 1 |
| 2026-09-03 | 222K | 255K | 87.0% | 115,460 |
| 2026-09-02 | 112K | 163K | 68.5% | 204 |
| 2026-09-01 | 55K | 99K | 56.1% | 4,519 |
| 2026-08-31 | 59K | 166K | 35.4% | 0 |
| 2026-08-28 | 57K | 79K | 72.2% | 0 |
| 2026-08-27 | 268K | 360K | 74.5% | 47,263 |
| 2026-08-26 | 67K | 91K | 73.6% | 0 |
| 2026-08-25 | 95K | 141K | 67.5% | 625 |
| 2026-08-24 | 93K | 124K | 75.4% | 150 |
| 2026-08-21 | 64K | 82K | 78.0% | 0 |
| 2026-08-20 | 85K | 110K | 77.3% | 0 |
| 2026-08-19 | 85K | 138K | 61.4% | 552 |
| 2026-08-18 | 196K | 299K | 65.4% | 0 |
| 2026-08-17 | 67K | 89K | 75.9% | 1 |
| 2026-08-14 | 48K | 79K | 60.7% | 0 |
| 2026-08-13 | 72K | 99K | 73.1% | 0 |
| 2026-08-12 | 79K | 173K | 45.7% | 0 |
| 2026-08-11 | 169K | 205K | 82.7% | 0 |
| 2026-08-10 | 235K | 263K | 89.6% | 0 |
| 2026-08-07 | 199K | 224K | 88.8% | 9,912 |
| 2026-08-06 | 44K | 55K | 79.3% | 0 |
| 2026-08-05 | 60K | 72K | 83.1% | 0 |
| 2026-08-04 | 74K | 152K | 49.0% | 0 |
| 2026-08-03 | 58K | 99K | 58.9% | 0 |
| 2026-07-31 | 81K | 105K | 77.3% | 300 |
Fails to deliver
SEC, by settlement date. JSONAs of 14 August 2026, the fails-to-deliver balance in MAZE is 35 shares, down 71 shares over the last settlement date. Over the last 52 readings it ranged from 2 shares (12 June 2026) to 62,407 shares (30 June 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-08-14 | 35 | $27.67 | $968 |
| 2026-08-07 | 106 | $28.53 | $3K |
| 2026-08-04 | 1,527 | $27.33 | $42K |
| 2026-07-27 | 40 | $27.68 | $1K |
| 2026-07-22 | 623 | $29.30 | $18K |
| 2026-07-17 | 8 | $27.17 | $217 |
| 2026-07-07 | 17,447 | $32.35 | $564K |
| 2026-07-02 | 817 | $29.81 | $24K |
| 2026-07-01 | 5,163 | $29.84 | $154K |
| 2026-06-30 | 62,407 | $29.00 | $1.8M |
| 2026-06-29 | 14,463 | $28.43 | $411K |
| 2026-06-26 | 38 | $27.02 | $1K |
| 2026-06-24 | 1,086 | $26.41 | $29K |
| 2026-06-23 | 10,187 | $25.57 | $260K |
| 2026-06-22 | 6,432 | $25.68 | $165K |
| 2026-06-15 | 243 | $24.05 | $6K |
| 2026-06-12 | 2 | $24.09 | $48 |
| 2026-06-03 | 1,004 | $24.29 | $24K |
| 2026-06-02 | 1,911 | $25.46 | $49K |
| 2026-06-01 | 488 | $26.46 | $13K |
| 2026-04-28 | 821 | $26.47 | $22K |
| 2026-04-20 | 357 | $28.09 | $10K |
| 2026-04-14 | 50,000 | $27.42 | $1.4M |
| 2026-04-09 | 250 | $28.09 | $7K |
| 2026-04-07 | 17 | $29.00 | $493 |
| 2026-04-01 | 71 | $29.85 | $2K |
| 2026-03-31 | 301 | $29.01 | $9K |
| 2026-03-27 | 56 | $31.71 | $2K |
| 2026-03-25 | 10,522 | $49.00 | $516K |
| 2026-03-24 | 7,646 | $49.00 | $375K |
Insider trades
SEC Form 4, newest first, 50 of 100 shown. JSONInsiders at MAZE reported 28 open-market sells worth $4.5M in the last 90 days and no open-market buys. Sells alone are a weak signal; insiders sell for tax, diversification and estate reasons all the time. Latest filing: Bernstein Harold (President, R&D & CMO) on 2026-09-04.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-09-04 | Bernstein Harold | President, R&D & CMO | Sell | 10K | $26.22 | $255K | 0 |
| 2026-09-03 | Dandekar Atul | CSBO | Sell | 36 | $25.81 | $929 | 32K |
| 2026-09-03 | Dandekar Atul | CSBO | Sell | 3K | $26.01 | $83K | 32K |
| 2026-09-03 | Courtney Phillips | GC and Corp. Secretary | Sell | 22 | $25.78 | $567 | 7K |
| 2026-09-03 | Courtney Phillips | GC and Corp. Secretary | Sell | 2K | $26.01 | $52K | 7K |
| 2026-09-03 | Coloma Jason V | Chief Executive Officer | Sell | 129 | $25.77 | $3K | 27K |
| 2026-09-03 | Coloma Jason V | Chief Executive Officer | Sell | 11K | $26.01 | $293K | 27K |
| 2026-09-03 | Bernstein Harold | President, R&D & CMO | Sell | 59 | $25.78 | $2K | 10K |
| 2026-09-03 | Bernstein Harold | President, R&D & CMO | Sell | 5K | $26.01 | $133K | 10K |
| 2026-09-02 | Dandekar Atul | CSBO | Sell | 391 | $27.12 | $11K | 36K |
| 2026-09-02 | Dandekar Atul | CSBO | Sell | 3K | $26.38 | $74K | 36K |
| 2026-09-02 | Courtney Phillips | GC and Corp. Secretary | Sell | 243 | $27.12 | $7K | 9K |
| 2026-09-02 | Courtney Phillips | GC and Corp. Secretary | Sell | 2K | $26.38 | $46K | 9K |
| 2026-09-02 | Coloma Jason V | Chief Executive Officer | Sell | 1K | $27.12 | $37K | 39K |
| 2026-09-02 | Coloma Jason V | Chief Executive Officer | Sell | 10K | $26.38 | $260K | 40K |
| 2026-09-02 | Bernstein Harold | President, R&D & CMO | Sell | 625 | $27.12 | $17K | 15K |
| 2026-09-02 | Bernstein Harold | President, R&D & CMO | Sell | 4K | $26.38 | $118K | 16K |
| 2026-09-01 | Dandekar Atul | CSBO | Option exercise | 13K | $0.00 | $0 | 39K |
| 2026-09-01 | Courtney Phillips | GC and Corp. Secretary | Option exercise | 11K | $0.00 | $0 | 11K |
| 2026-09-01 | Coloma Jason V | Chief Executive Officer | Option exercise | 50K | $0.00 | $0 | 50K |
| 2026-09-01 | Coloma Jason V | Chief Executive Officer | Sell | 32K | $26.29 | $839K | 223K |
| 2026-09-01 | Coloma Jason V | Chief Executive Officer | Sell | 3K | $26.31 | $68K | 18K |
| 2026-09-01 | Bernstein Harold | President, R&D & CMO | Option exercise | 20K | $0.00 | $0 | 20K |
| 2026-09-01 | Bernstein Harold | President, R&D & CMO | Sell | 16K | $26.36 | $426K | 0 |
| 2026-09-01 | Bernstein Harold | President, R&D & CMO | Option exercise | 16K | $10.42 | $168K | 16K |
| 2026-08-28 | Dandekar Atul | CSBO | Sell | 8K | $27.58 | $207K | 26K |
| 2026-08-28 | Dandekar Atul | CSBO | Option exercise | 8K | $10.42 | $78K | 34K |
| 2026-08-13 | Bernstein Harold | President, R&D & CMO | Sell | 16K | $27.61 | $446K | 0 |
| 2026-08-13 | Bernstein Harold | President, R&D & CMO | Option exercise | 16K | $10.42 | $168K | 16K |
| 2026-08-03 | Coloma Jason V | Chief Executive Officer | Sell | 2K | $27.09 | $43K | 255K |
| 2026-08-03 | Coloma Jason V | Chief Executive Officer | Sell | 30K | $26.71 | $810K | 257K |
| 2026-08-03 | Coloma Jason V | Chief Executive Officer | Sell | 154 | $27.09 | $4K | 21K |
| 2026-08-03 | Coloma Jason V | Chief Executive Officer | Sell | 2K | $26.71 | $65K | 21K |
| 2026-07-29 | Dandekar Atul | CSBO | Sell | 400 | $27.89 | $11K | 26K |
| 2026-07-29 | Dandekar Atul | CSBO | Sell | 7K | $27.31 | $194K | 27K |
| 2026-07-29 | Dandekar Atul | CSBO | Option exercise | 8K | $10.42 | $78K | 34K |
| 2026-06-01 | Coloma Jason V | Chief Executive Officer | Sell | 553 | $26.24 | $15K | 28K |
| 2026-06-01 | Coloma Jason V | Chief Executive Officer | Sell | 6K | $26.20 | $160K | 345K |
| 2026-06-01 | Bernstein Harold | President, R&D & CMO | Sell | 2K | $26.36 | $42K | 0 |
| 2026-06-01 | Bernstein Harold | President, R&D & CMO | Sell | 13K | $25.57 | $339K | 2K |
| 2026-06-01 | Bernstein Harold | President, R&D & CMO | Option exercise | 15K | $10.42 | $155K | 15K |
| 2026-05-29 | Dandekar Atul | CSBO | Sell | 8K | $26.34 | $198K | 25K |
| 2026-05-29 | Dandekar Atul | CSBO | Option exercise | 8K | $10.42 | $78K | 32K |
| 2026-05-26 | Coloma Jason V | Chief Executive Officer | Sell | 26K | $26.02 | $666K | 351K |
| 2026-05-22 | Coloma Jason V | Chief Executive Officer | Sell | 2K | $26.00 | $64K | 29K |
| 2026-05-22 | Coloma Jason V | Chief Executive Officer | Sell | 5K | $26.00 | $117K | 377K |
| 2026-05-15 | Coloma Jason V | Chief Executive Officer | Sell | 116 | $26.00 | $3K | 31K |
| 2026-05-15 | Coloma Jason V | Chief Executive Officer | Sell | 2K | $26.00 | $47K | 381K |
| 2026-05-14 | Bernstein Harold | President, R&D & CMO | Sell | 15K | $26.22 | $393K | 0 |
| 2026-05-14 | Bernstein Harold | President, R&D & CMO | Option exercise | 15K | $10.42 | $156K | 15K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are the rarer, stronger signal.
Planned sales (Form 144)
Newest first. JSON8 Form 144 notices on file for MAZE worth $3.9M at the prices reported; 8 in the last 90 days worth $3.9M. Latest: HAROLD BERNSTEIN filed on 2026-09-04 to sell 9,705 shares ($251K) from 2026-09-04.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-09-04 | HAROLD BERNSTEINOfficer | 10K | $251K | 0.017% | 2026-09-04 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-09-02 | Atul DandekarOfficer | 7K | $177K | 0.012% | 2026-09-02 | Morgan Stanley Smith Barney LLC |
| 2026-09-02 | Courtney PhillipsOfficer | 4K | $110K | 0.007% | 2026-09-02 | Morgan Stanley Smith Barney LLC |
| 2026-09-02 | Jason V ColomaOfficer | 23K | $623K | 0.042% | 2026-09-02 | Morgan Stanley Smith Barney LLC |
| 2026-09-02 | Harold BernsteinOfficer | 11K | $284K | 0.019% | 2026-09-02 | Morgan Stanley Smith Barney LLC |
| 2026-09-01 | Coloma Jason VOfficer | 35K | $908K | 0.062% | 2026-09-01 | UBS Financial Services Inc. |
| 2026-08-03 | Coloma Jason VOfficer | 35K | $923K | 0.062% | 2026-08-03 | UBS Financial Services Inc. |
| 2026-07-29 | ATUL DANDEKAROfficer | 23K | $627K | 0.041% | 2026-07-29 | Morgan Stanley Smith Barney LLC Executive Financial Services |
Large holders (13D and 13G)
One row per reporting person, newest filing first. JSON5 holders above 5% have filed on MAZE, all on Schedule 13G (passive). The largest reported stake is BlackRock, Inc. at 5.4% of the class (2,978,114 shares), filed 2026-07-29 for an event on 2026-06-30.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-08-14 | 13G/Ano. 1 | Paradigm BioCapital Advisors LPpartnership | 0 | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | Paradigm BioCapital Advisors GP LLCother entity | 0 | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | Senai Asefaw, M.D.individual | 0 | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | Paradigm BioCapital International Fund Ltd.corporation | 0 | 0.0% | 2026-06-30 |
| 2026-07-29 | 13G | BlackRock, Inc.parent holding company | 3.0M | 5.4% | 2026-06-30 |
13F holders
Tracked managers holding MAZE at their latest 13F. JSON4 of the 30 tracked managers held MAZE at their latest 13F, $33.0M in total at quarter-end prices. Citadel Advisors is the largest at $26.1M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 2 added shares and 2 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Citadel Advisors | 2026-06-30 | 875K | $26.1M | 0.00% | +66K |
| Two Sigma Investments | 2026-06-30 | 193K | $5.8M | 0.00% | +177K |
| AQR Capital Management | 2026-06-30 | 27K | $810K | 0.00% | -784 |
| D. E. Shaw & Co. | 2026-06-30 | 12K | $359K | 0.00% | -34K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
What this page is
Maze Therapeutics, Inc. in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page pulls every series the site collects for one ticker onto one URL, keyed by the SEC's own ticker list, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a summary sentence built from the rows (last value, change, range with dates) and its own JSON and CSV links. Nothing on the page is written by a model; the sentences change only when the data does. A page exists only for companies with data in at least two series, and every section says when its source last updated.
This page follows Maze Therapeutics, Inc. (MAZE), SEC CIK 1842295, listed on Nasdaq, classified by the SEC as biological products, (no diagnostic substances). The cross-market tables live on the short interest and insider transactions hubs.
Source and method
- Short interest
- FINRA consolidated short interestTwice a month, about eight business days after settlement. Latest 2026-08-14.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesEvery trading day, loaded the following morning. Latest 2026-09-11.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataTwice a month, a few weeks after the half month ends. Latest 2026-08-14.JSON and CSV
- Planned sales
- SEC EDGAR Form 144EDGAR read every 30 minutes; a notice is filed on or before the sell order. Latest 2026-09-04.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GEDGAR read every 30 minutes; 13D within five business days of crossing 5%, 13G on the passive schedule. Latest 2026-08-14.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRQuarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Insider trades
- SEC EDGAR Form 4EDGAR read every 30 minutes; filings are due two business days after the trade. Latest 2026-09-04.JSON and CSV
- Company record
- EDGAR filing index for CIK 1842295Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 30 requests a minute without a key, 120 a minute with a key from a free account.
Data checks. Every dataset is checked against its source once a day. This dataset passed the last run, 13 Sep 09:50 UTC.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a crowded short are the combination that has historically preceded squeezes; insider sells next to a crowded short are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as biological products, (no diagnostic substances)
- KYMRKymera Therapeutics, Inc.
- ADPTAdaptive Biotechnologies Corp
- TWSTTwist Bioscience Corp
- HALOHALOZYME THERAPEUTICS, INC.
- KRYSKrystal Biotech, Inc.
- NBIXNEUROCRINE BIOSCIENCES INC
- RVMDRevolution Medicines, Inc.
- AMGNAMGEN INC
- GILDGILEAD SCIENCES, INC.
- RXRXRECURSION PHARMACEUTICALS, INC.
- APGEApogee Therapeutics, Inc.
- FENCFENNEC PHARMACEUTICALS INC.
- PCVXVaxcyte, Inc.
- BIIBBIOGEN INC.
- VORVor Biopharma Inc.
- EXELEXELIXIS, INC.
- SRRKScholar Rock Holding Corp
- ADMAADMA BIOLOGICS, INC.
- VCELVericel Corp
- TECHBIO-TECHNE Corp
- ARTVArtiva Biotherapeutics, Inc.
- BCRXBIOCRYST PHARMACEUTICALS INC
- VIRVir Biotechnology, Inc.
- IOVAIOVANCE BIOTHERAPEUTICS, INC.
Datasets
Frequently Asked Questions
How much of MAZE is sold short?
What is MAZE's daily short volume?
Does MAZE have fails to deliver?
Are MAZE insiders buying or selling?
Have MAZE insiders filed to sell?
Who owns more than 5% of MAZE?
Which funds hold MAZE?
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.